Literature DB >> 17596142

Challenges in defining type 2M von Willebrand disease: results from a Canadian cohort study.

P D James1, C Notley, C Hegadorn, M-C Poon, I Walker, D Rapson, D Lillicrap.   

Abstract

BACKGROUND/
METHODS: In order to better characterize the genotype-phenotype correlation in type 2M von Willebrand disease (VWD), we sequenced the coding region for the mature subunit of the von Willebrand factor (VWF) gene (exons 18-52, including exon/intron boundaries) in 16 index cases originally submitted to the Canadian Type 1 VWD Study as type 1 VWD, but reclassified as type 2M VWD on the basis of phenotype (excessive mucocutaneous bleeding and von Willebrand factor: antigen (VWF:Ag) and/or von Willebrand factor: ristocetin cofactor (VWF:RCo) between 0.05 and 0.50 IU mL(-1) on at least two occasions and RCo/Ag ratio < 0.6 and no loss of high molecular weight multimers). Available family members (16 affected, 23 unaffected and six unknown) were sequenced for identified mutations.
RESULTS: We identified eight different missense mutations (R854Q, T1054M, R1315C, R1374C, R1374H, L1382P, S2179F, and T2647M) within these 16 families. We were significantly more likely to identify a VWF mutation in cases with RCo/Ag ratios < 0.50 (P < 0.05, chi-squared test). Importantly, every index case with an RCo/Ag ratio < 0.40 (4/4 index cases) had a mutation identified within the A1 domain, in contrast to 1/12 cases with an RCo/Ag ratio > 0.40. Difficulties with the standardization of the VWF:RCo may be responsible for the heterogeneity in cases with RCo/Ag ratios between 0.40 and 0.60.
CONCLUSIONS: The genotype-phenotype correlation for cases with RCo/Ag ratios < 0.40 is clear. On the basis of our results, the phenotypic definition of type 2M VWD may need to be more stringent, and should be the subject of an international standardization initiative.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17596142     DOI: 10.1111/j.1538-7836.2007.02666.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  16 in total

1.  Translational medicine advances in von Willebrand disease.

Authors:  D Lillicrap
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

Review 2.  von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies.

Authors:  Paula D James; David Lillicrap
Journal:  Am J Hematol       Date:  2012-03-03       Impact factor: 10.047

3.  Variable bleeding phenotype in an Amish pedigree with von Willebrand disease.

Authors:  Sweta Gupta; Meadow Heiman; Natalie Duncan; Jesse Hinckley; Jorge Di Paola; Amy D Shapiro
Journal:  Am J Hematol       Date:  2016-08-22       Impact factor: 10.047

4.  Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD.

Authors:  Veronica H Flood; Joan Cox Gill; Patricia A Morateck; Pamela A Christopherson; Kenneth D Friedman; Sandra L Haberichter; Raymond G Hoffmann; Robert R Montgomery
Journal:  Blood       Date:  2010-12-10       Impact factor: 22.113

5.  Clinical and laboratory phenotype variability in type 2M von Willebrand disease.

Authors:  A L Doruelo; S L Haberichter; P A Christopherson; L N Boggio; S Gupta; S R Lentz; A D Shapiro; R R Montgomery; V H Flood
Journal:  J Thromb Haemost       Date:  2017-06-23       Impact factor: 5.824

6.  Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease.

Authors:  D M Larsen; S L Haberichter; J C Gill; A D Shapiro; V H Flood
Journal:  Haemophilia       Date:  2013-03-18       Impact factor: 4.287

7.  Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function.

Authors:  V H Flood; K D Friedman; J C Gill; P A Morateck; J S Wren; J P Scott; R R Montgomery
Journal:  J Thromb Haemost       Date:  2009-08-19       Impact factor: 5.824

Review 8.  The molecular characterization of von Willebrand disease: good in parts.

Authors:  P D James; D Lillicrap
Journal:  Br J Haematol       Date:  2013-02-14       Impact factor: 6.998

Review 9.  von Willebrand disease.

Authors:  Paula D James; Anne C Goodeve
Journal:  Genet Med       Date:  2011-05       Impact factor: 8.822

10.  Laboratory variability in the diagnosis of type 2 VWD variants.

Authors:  Stefanie DiGiandomenico; Pamela A Christopherson; Sandra L Haberichter; Thomas C Abshire; Robert R Montgomery; Veronica H Flood
Journal:  J Thromb Haemost       Date:  2020-11-10       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.